GSK
GSK plcMarquee-fund ownership over time
This quarter's activity
New positions opened
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates | Q4 2022 | 15Q | $29 | $50 | +74% |
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $37 | $50 | +35% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $38 | $50 | +32% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $38 | $50 | +32% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 2× in & out | Q1 2026 | Q2 2026 | → $50 | -17% |
| Two Sigma Investments | Q4 2024 | Q2 2026 | → $50 | +55% |
| D.E. Shaw 2× in & out | Q1 2026 | Q2 2026 | → $50 | -17% |
| Point72 Asset Management | Q1 2026 | Q2 2026 | → $50 | -17% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at GSK plc. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Dec 15, 2025 — the most recent Form 4 on file — not from today.
Fundamentals
XBRL · GSK plcNot enough XBRL history to plot. GSK plchasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for GSK plc — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 6-KDIRECTOR/PDMR SHAREHOLDINGJun 10, 2026
- 6-KDR HAL BARRON - NEW DIRECTORSHIPJun 9, 2026
- 6-KGSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC.Jun 9, 2026
- 6-KTRANSACTION IN OWN SHARESJun 8, 2026
- 6-KTOTAL VOTING RIGHTSJun 1, 2026
- 6-KTRANSACTION IN OWN SHARESJun 1, 2026
- 6-KPOSITIVE PHASE 3 DATA FOR BEPIROVIRSENMay 28, 2026
- 6-KDIRECTOR/PDMR SHAREHOLDINGMay 27, 2026
- 6-KADMISSION TO TRADINGMay 26, 2026
- 6-KTRANSACTION IN OWN SHARESMay 26, 2026
- 6-KQ2 2026 RESULTS DATE CONFIRMED - 28 JULY 2026May 22, 2026
- 6-KDIRECTOR/PDMR SHAREHOLDINGMay 20, 2026
- 6-KDIRECTOR/PDMR SHAREHOLDINGMay 20, 2026
- 6-KDIRECTOR/PDMR SHAREHOLDINGMay 19, 2026
- 6-KTRANSACTION IN OWN SHARESMay 18, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q1 2026 | Q2 2026 | $60 | $50 | -17% |
| D.E. Shaw | Q1 2026 | Q2 2026 | $60 | $50 | -17% |
| Point72 Asset Management | Q1 2026 | Q2 2026 | $60 | $50 | -17% |
| Two Sigma Investments | Q4 2024 | Q2 2026 | $32 | $50 | +55% |
| D.E. Shaw | Q4 2024 | Q2 2025 | $32 | $36 | +12% |
| Citadel Advisors | Q3 2024 | Q4 2025 | $38 | $46 | +22% |
| AQR Capital Management | Q3 2024 | open | $38 | $50 | +32% |
| Millennium Management | Q3 2024 | open | $38 | $50 | +32% |
| Renaissance Technologies | Q3 2024 | open | $37 | $50 | +35% |
| Bridgewater Associates | Q4 2022 | open | $29 | $49 | +69% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.